University Of Minnesota Task Force Seeks Greater Transparency In Faculty Conflicts Of Interest With Pharmaceutical Companies A task force that examined conflicts of interest at the University of Minnesota Medical School has recommended that the university expand its disclosure policy regarding relationships between the school's faculty and the drug industry, the AP/Fargo Forum reports.
Source: www.medicalnewstoday.comDistrict Court Affirms Patent Infringement Rulings And Finds That Amgen Is Entitled To A Permanent Injunction Against Roche Amgen (NASDAQ:AMGN) announced today that the United States (U.S.) District Court in Boston issued its written decision upholding the prior jury verdict and court rulings regarding the infringement, validity and enforceability of 10 claims of four of Amgen's erythropoietin (EPO) patents. The Court also ruled that Amgen is entitled to a permanent injunction prohibiting Roche from selling its pegylated-erythropoietin (peg-EPO) product MIRCERA in the U.S.
Source: www.medicalnewstoday.comSenate Approves Financial Bailout Legislation That Includes Mental Health Parity Provisions Mental
health parity legislation was included in the $700 billion bailout of Wall Street firms passed Wednesday by the Senate, the AP/Detroit Free Press reports. The legislation would require group
health plans of 51 or more employees to cover mental illnesses at the same level as physical ailments.
Source: www.medicalnewstoday.comNew Report Calls For Mental Health To Be Better Integrated Into Primary Care The World
Health Organization (WHO) and The World Organization of Family Doctors (Wonca) today released a joint report that aims to offer help to hundreds of millions of people who are affected by mental disorders but cannot receive the care and treatment they need.
Source: www.medicalnewstoday.comDeveloping GA101, A Humanized Anti-CD20 Monoclonal Antibody With Hematological Malignancies Potential Treatment - Genentech, GlycArt And Roche Collabo Genentech, Inc. (NYSE:DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX:ROG) have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt's GA101 molecule.
Source: www.medicalnewstoday.comCardinal Health Inc., Agrees To Pay $34 Million To Settle Claims That It Failed To Report Suspicious Sales Of Widely-Abused Controlled Substance Cardinal
Health Inc., one of the nation's largest distributors of pharmaceutical
drugs, has agreed to settle allegations that it violated federal reporting provisions relating to its handling of certain controlled substances regulated by the Drug Enforcement Administration (DEA). Under the agreement between the company and seven U.S.
Source: www.medicalnewstoday.comAccess Pharmaceuticals Presents New Data On The Company's Angiolix(R) Therapeutic Monoclonal Antibody Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves.
Source: www.medicalnewstoday.comBiotechnology Industry Organization Lauds Senate Passage Of Strengthened Two-Year R&D Credit, USA Urges House to Pass Economic Stabilization Package, to Bolster Investor Confidence and Hasten Therapeutic Development The Biotechnology Industry Organization (BIO) today lauded U.S. Senate passage of a 2-year extension of the federal research and development (R&D) tax credit and urged the House to pass the package when it is considered on Friday. The R&D tax credit extension is part of the "Emergency Economic Stabilization Act of 2008.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 PM
